Safety and efficacy of fasting among Diabetic populatio
Phase 2
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2023/02/049866
- Lead Sponsor
- Sant Hirdaram yoga and nature cure hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Type 2 diabetes mellitus
Age between 35 to 65 years
Willing to fast and give consent
Exclusion Criteria
Any type of Diabetes related complications like nephropathy, retinopathy and neuropathy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fasting blood sugar <br/ ><br>post prandial blood sugar <br/ ><br>Diabetes related quality of life questionnaire <br/ ><br>Timepoint: Day 1(before fasting) and day 9(after fasting)
- Secondary Outcome Measures
Name Time Method rine ketone bodies <br/ ><br>Uric acid <br/ ><br>Urine PH <br/ ><br>Timepoint: Day 3 of fasting and day 8 of fasting
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are modulated by fasting therapy in type 2 diabetes mellitus patients?
How does fasting therapy compare to metformin or GLP-1 agonists in glycemic control and safety for T2DM?
Which biomarkers (e.g., HbA1c, adiponectin) predict response to fasting interventions in T2DM populations?
What are the potential adverse events of prolonged fasting in T2DM patients and their management strategies?
How do fasting protocols synergize with SGLT2 inhibitors or DPP-4 inhibitors in diabetes treatment regimens?